Advanced Medical Solutions Group plc announced that it has signed an agreement to commercialise LiquiBandFix8 in the US with TELA Bio, Inc. Under the terms of the agreement, TELA Bio will market and distribute LiquiBandFix8 under the brand name LIQUIFIX via its direct specialist sales team across the United States with official launch at the American Hernia Society Annual Meeting, taking place from 21-23 September. This represents a significant commercial opportunity for AMS and TELA Bio as they enter a new addressable market estimated at $200 million. Headquartered in Malvern, Pennsylvania, TELA Bio has an established and fast-growing footprint in the US market with products that focus on addressing the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic reconstructive surgery.

To service its growing product portfolio, TELA Bio has projected that its salesforce is expected to reach 75-80 representatives by the end of 2023. TELA Bio generated revenues of $41.4 million (+41%) in 2022 and $26.4 million (+42%) in Hernia Society, with full year 2023 guidance of $60-65 million. The signing of this agreement concludes a comprehensive selection process involving a number of potential partners with a broad range of strengths and marketing strategies.

The outcome of this process made it clear that TELA Bio brings the right combination of strengths and attributes, with a vision and ambition that is closely aligned with and complements AMS' strategy and aspirations. LiquiBandFix8®? /LIQUIFIX??

is already marketed in Europe and other non-US territories and delivered strong growth in these markets in 2021, 2022 and 2023 year to date. AMS' experience in commercialising the product in these markets has emphasised the importance of using specialist sales operations. TELA Bio is an ideal partner for LiquiBandFix8/LIQUIFIX??

in the US with its hernia repair specialism, its focus on education and training, and its commitment to improving patient outcomes through new technologies that address the shortcomings of existing devices. In June 2023, LiquiBandFix8/LIQUIFIX?? was granted Pre-Market Approval (PMA) by the US Food and Drug Administration (FDA) for its use in hernia repair surgery.

The device uses drops of cyanoacrylate adhesive instead of sharp tacks to fix mesh to tissue inside the body during open and laparoscopic hernia surgery. It is the first product of its kind to be approved in the US and will benefit patients as the less invasive application is expected to reduce pain and other post-operative complications.